Sanofi SA completed three acquisitions in the second quarter, signalling a new direction for research and development and potentially lifting the company’s dependence on sales of the immunology drug Dupixent. Acquisitions of Kiadis Pharma, a cell therapy company; Kymab Group, an antibody developer; and Tidal Therapeutics, a company with messenger RNA (mRNA) technology, were completed in April.
